Julia Scarisbrick, MD

Julia Scarisbrick, MD, explains how better recognition of mogamulizumab-associated rash is moving the drug earlier in the mycosis fungoides and Sézary treatment course.

Julia Scarisbrick reviews real-world data showing mogamulizumab eased itch, pain, flaking, sleep, and fatigue in MF and Sézary syndrome as early as 4 weeks.